Involvement of PrP(C) in kainate-induced excitotoxicity in several mouse strains. by Carulla Martí, Patricia et al.
1Scientific RepoRts | 5:11971 | DOi: 10.1038/srep11971
www.nature.com/scientificreports
Involvement of PrPC in kainate-
induced excitotoxicity in several 
mouse strains
Patricia Carulla1,2,3, Franc Llorens1,2,3,4, Andreu Matamoros-Angles1,2,3, Patricia  
Aguilar-Calvo5, Juan Carlos Espinosa5, Rosalina Gavín1,2,3, Isidre Ferrer6,7, 
Giuseppe Legname8, Juan Maria Torres5 & José A. del Río1,2,3
The cellular prion protein (PrPC) has been associated with a plethora of cellular functions ranging 
from cell cycle to neuroprotection. Mice lacking PrPC show an increased susceptibility to epileptic 
seizures; the protein, then, is neuroprotective. However, lack of experimental reproducibility has 
led to considering the possibility that other factors besides PrPC deletion, such as the genetic 
background of mice or the presence of so-called “Prnp flanking genes”, might contribute to the 
reported susceptibility. Here, we performed a comparative analysis of seizure-susceptibility using 
characterized Prnp+/+ and Prnp0/0 mice of B6129, B6.129, 129/Ola or FVB/N genetic backgrounds. 
Our study indicates that PrPC plays a role in neuroprotection in KA-treated cells and mice. For 
this function, PrPC should contain the aa32–93 region and needs to be linked to the membrane. In 
addition, some unidentified “Prnp-flanking genes” play a role parallel to PrPC in the KA-mediated 
responses in B6129 and B6.129 Prnp0/0 mice.
Although the role of the cellular form of the prion protein (PrPC) in living organisms has been inten-
sively studied, a clear consensus concerning the physiological functions of this protein is still elusive and 
controversial. To date, existing evidence implicates PrPC in numerous distinct cellular processes, includ-
ing cell proliferation and differentiation1,2, copper homeostasis3,4, oxidative stress5 and cell signaling6,7, 
among others.
The generation of different transgenic Prnp0/0 mice (mixed B6129 PrnpZrchl/Zrchl or co-isogenic 129/
Ola PrnpEdbg/Edbg backgrounds) in the early 1990s did not reveal any relevant phenotypic alteration of the 
mutant mice8,9. However, subsequent studies identified an abundance of phenotypic alterations (e.g.,10), 
including depressive-like behaviour11, cognitive deficits12, age-dependent behavioural abnormalities13, 
altered olfaction14, peripheral myelin deficits15, altered circadian rhythms16 and an increased suscepti-
bility to oxidative stress5 and glutamate excitotoxicity17–19. Indeed, different laboratories have described 
in these strains and in congenic B6.129 PrnpZrchl/Zrchl (B6129 mice backcrossed with C57BL/6 for several 
generations) an enhanced sensitivity to seizures after the administration of epileptogenic drugs such as 
kainic acid (KA), N-methyl-d-aspartic acid (NMDA), pilocarpine and pentylenetetrazol (PTZ), suggest-
ing a neuroprotective role of the protein against excitotoxic insults (e.g.,17–21). However, some studies sug-
gest that PrPC is not involved in KA-mediated excitotoxicity and that the observed differences are likely 
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to be associated with the genetic background of the mice used in the experiments22–24. In fact, it was 
described some years ago how different mouse strains exhibit different vulnerability to the administra-
tion of glutamate and other seizure-inducing drugs, which correlates with differences in axonal sprouting 
and cell death in the hippocampal region (e.g.,25,26). For example, the hippocampus of the C57BL/6 back-
ground mouse, in contrast to FVB/N, is more resistant to the excitotoxic effects of KA25,27–29. Thus, these 
genetic differences dilute the specific participation of PrPC in KA-mediated cell death. However, these 
genomic influences do not per se explain the neuroprotective properties of PrPC observed in KA-treated 
neuroblastoma cell lines carrying different dosages of the Prnp gene (see below).
In addition to these genetic differences, a number of Prnp-flanking genes associated with the 129 
genotype in B6129 PrnpZrchl/Zrchl mixed mice30 have recently been described. These genes are retained in 
Prnp0/0 progeny of congenic B6.129 PrnpZrchl/Zrchl after numerous (> 10) crosses30,31 with C57BL/6 mice. 
SNP analysis of the backcrossed mice indicated that after 5 to 6 rounds the amount of C57BL/6-associated 
SNP increased from ≈ 60 up to ≈ 93%. Thus, B6.129 PrnpZrchl/Zrchl wild type and mutant mice may still 
differ at these additional polymorphic loci associated with Prnp32,33. One of these loci, the signal regula-
tory protein alpha (SIRPα ) has recently been described as responsible for a previously PrPC-associated 
phagocytic function in macrophages33. More relevantly, overexpressing mice (Tg20) generated in mixed 
B6129 PrnpZrchl/Zrchl congenic mouse carried several copies of the polymorphic loci, since in most cases 
they are also crossed with previously backcrossed B6.129 PrnpZrchl/Zrchl mice30. In this scenario, it is rea-
sonable to consider that the data obtained using Prnp0/0 or Tg20 (backcrossed or not with C57BL/6) in 
electrophysiological studies may yield conflicting results24,34–36. Indeed, lack of PrPC has been associated 
with long-term potentiation (LTP), GABA-mediated fast after hyperpolarization (AHP) and paired pulse 
facilitation (PPF) abnormalities in mutant mice (e.g.,37–40). However, regulatory participation of PrPC 
in neurotransmission and neuroprotection and in other cellular functions has also been shown with 
acute modulation of Prnp expression in neural cell lines and in other organisms (e.g., zebrafish) as 
models, to avoid the above-mentioned genetic problems of mice. For example, neuroblastoma (N2a) 
cells with reduced Prnp expression are more susceptible to KA in contrast to non-modified cells18,20. 
Functions of PrPC in neurotransmission are also reinforced since i) PrPC seems to be located in the 
synaptic cleft20,41–43; ii) several synaptic proteins (e.g., synaptophysin, synapsin Ib)44,45, glutamate receptor 
subunits (e.g., GluR6/7, NR2D, GluR1/2, mGluR1/5)19,20,46,47 and ion channels36 have been identified as 
interacting partners of PrPC; iii) PrPC regulates GluR6/7-mediated signalling through the modulation 
of the formation of the GluR6/7-PSD-95-MLK3 trimeric complex, which triggers the activation of the 
JNK3 apoptotic pathway in the hippocampus in response to KA administration20; and iv) it modulates 
the NMDA receptor48.
Due to these conflicting results, we aimed to clarify the participation of PrPC in KA-mediated exci-
totoxicity in vivo, using B6129 PrnpZrchl/Zrchl, B6.129 PrnpZrchl/Zrchl, 129/Ola PrnpEdbg/Edbg and FVB Prnp0/0 
and Prnp+/+ mice, and in vitro using N2a cells. In addition, we wished to explore whether the expression 
of truncated forms of PrPC (Δ F35 or Δ C4) lacking 32–134 and 32–93 residues of PrPC might increase 
the neurotoxic effects.
Our results indicate that FVB/N Prnp0/0 mice are not suitable for the in vivo model of KA-mediated 
excitotoxicity due to the intrinsic sensitivity to KA of FVB/N mice that hides clear differences49,50. More 
relevantly, both B6129 PrnpZrchl/Zrchl and co-isogenic 129/Ola PrnpEdbg/Edbg mice display more severe epi-
leptic episodes and neurotoxic brain damage than their corresponding wild-type controls. Backcrossed 
B6.129 PrnpZrchl/Zrchl mice (with ≈ 93% of C57BL/6 SNPs) displayed lower numbers of seizures com-
pared to B6129, indicating additional participation of Prnp-linked genes in KA-mediated effects in B6129 
PrnpZrchl/Zrchl mice. However, our data using co-isogenic 129/Ola PrnpEdbg/Edbg (100% 129 genotype) and 
cell lines reinforce the notion that PrPC is neuroprotective in KA treatment. In addition, the expression 
of Δ F35 and Δ C4 in a B6129 PrnpZrchl/Zrchl background increased hippocampal cell death, especially in 
the CA3 region after KA injections. These in vivo data were also corroborated using N2a cells transiently 
expressing N-terminal truncated forms of PrPC. Lastly, our in vitro experiments also suggest that to be 
neuroprotective, PrPC should be bound to the plasma membrane by means of the GPI moiety.
Results
KA-induced seizures in several strains of wild-type and PrPC-null mice. A gene-targeting strat-
egy to generate null mutations in mice is a powerful research tool to reveal in vivo the function of a 
single protein, as derived phenotypic alterations are usually attributed to the deleted gene. Nevertheless, 
behavioural alterations observed in null-mutant mice could result in some cases from the genetic back-
ground (see introduction, see also26,49,50). In order to determine a possible influence of non-Prnp genes 
in the susceptibility to KA-induced seizures, we compared the epileptic response in B6129 (n = 20), 129/
Ola PrnpEdbg/Edbg (n = 9) and FVB/N Prnp0/0 (n = 7) and wild type mice (B6129, n = 16; 129/Ola PrnpEdbg/Edbg 
(n = 11); FVB/N (n = 8) (Fig.  1a and Supplementary Tables 1–6). A multiple administration protocol, 
consisting of three intraperitoneal injections of KA (10 mg/kg body weight) at 30 min intervals, was 
used in this experiment. Seizure intensity was analysed during the 4 hours after the first KA injection 
and scored as indicated in Methods. For an easier comparative analysis, data from grades I to IV were 
grouped together.
After the behavioural study, mice were numbered and kept in separate boxes until histological studies. 
Percentages of the different strains of mice reaching each stage were represented (Fig. 1a). As indicated 
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Figure 1. Comparison of KA-induced seizure profile in Prnp+/+and Prnp0/0 mice on B6129, B6.129, 129/
Ola or FVB/N genetic backgrounds. (a) Percentage of mice reaching seizure stages I to VI and KA-induced 
mortality. Adult animals were subjected to a multiple KA-injection protocol (10 mg/kg b.w.) and epileptic 
responses were analysed during 4 hours after the first KA injection (see Methods for details).(b) Example 
of the western blot detection of PrPC (6H4) expression in brain extracts obtained from B6129 PrnpZrchl/Zrchl 
Prnp+/+, B6129 PrnpZrchl/Zrchl Prnp0/0, 129/Ola PrnpEdbg/Edbg Prnp+/+, 129/Ola PrnpEdbg/Edbg Prnp0/0, FVB/N 
Prnp+/+ and FVB/N Prnp0/0 mice. Tubulin was used as a loading control. (c) Photomicrographs showing 
the pattern of neurodegeneration (Fluoro-Jade B staining) and DAPI staining of hippocampus in B6129 
PrnpZrchl/Zrchl Prnp+/+, B6129 PrnpZrchl/Zrchl Prnp0/0, 129/Ola PrnpEdbg/Edbg Prnp+/+, 129/Ola PrnpEdbg/Edbg Prnp0/0, 
24 hours after KA treatment. Dying cells are mainly located in the pyramidal cell layer of CA1 and CA3 
regions of B6129 PrnpZrchl/Zrchl Prnp0/0 and 129/Ola PrnpEdbg/Edbg Prnp0/0 mice respectively. (d) Time course of 
stage VI seizure during the first 30 min, from 30–60 min and from 60–180 minutes, of adult B6129 PrnpZrchl/
Zrchl Prnp0/0 vs B6.129 PrnpZrchl/Zrchl Prnp0/0. Data are presented as the mean ± S.E.M. of the number of 
seizures/number of animals. Note the lower levels of seizures in parallel with decreased 129 associated genes 
in B6.129 PrnpZrchl/Zrchl Prnp0/0 mice. Abbreviations: sr, stratum radiatum; sl, stratum lucidum; slm, stratum 
lacunosum-moleculare; sp, stratum pyramidale; so, stratum oriens. Scale bar represents 200 μ m. Asterisks 
indicate statistical significance (***P < 0.01, Mann-Whitney U test).
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(Fig.  1a and Supplementary Tables 1–6), all mice achieved stages I–IV, developing hypoactivity and 
immobility shortly after the first injection. When comparing wild type vs Prnp-null mice, significant differ-
ences were observed in the percentage of mice reaching stages V and VI, with the B6129 PrnpZrchl/Zrchl and 
129/Ola PrnpEdbg/Edbg much more susceptible to seizures than their respective Prnp+/+ controls (Fig. 1a 
and Supplementary Movies 1 and 2). In both groups, a high percentage of Prnp-null mice (100% and 75% 
respectively) developed loss of balance control and intermittent whole-body convulsions. More severe 
seizure activity, consisting of continuous seizures and/or ‘popcorn’ bouncing behaviour (stage VI) was 
also reported, leading to the death of 20% of the B6129 PrnpZrchl/Zrchl mice tested. In contrast, no B6129 
Prnp+/+ or 129/Ola Prnp+/+ mice reached stage VI or died during experiments.
Distinct results were obtained when analysing FVB/N mice, since no significant differences were 
observed between FVB/N Prnp+/+ and FVB/N Prnp0/0 animals, and only a 9% difference was observed 
between them (Fig. 1a and Supplementary Movie 3). FVB/N Prnp+/+ showed a high epileptic response 
at 10 mg/kg b.w of KA (≈ 50%), which was not observed in B6129 Prnp+/+ (≈ 30%) and 129/Ola Prnp+/+ 
(0%); it occurred in all described behavioural stages, but without any reported deaths. Although other 
unknown factors might be involved, such phenotypical differences between Prnp+/+ mouse strains could 
be related to small differences in PrPC expression levels, since our western blot analysis revealed lower 
PrPC expression in FVB/N Prnp+/+ (0.623 ± 0.04) compared to 129/Ola Prnp+/+ (0.92 ± 0.038) mice 
( t = 4.21, mean diff. = 0.30; 95% Cl of diff. = 0.66 to 0.54) but not between B6129 Prnp+/+ (0.84 ± 0.063) 
and FVB/N Prnp+/+ mice (t = 3,104, mean diff. = 0.22; 95% Cl of diff. = 0.− 0.013 to 0.459), or between 
B6129 Prnp+/+ and 129/Ola Prnp+/+ ( t = 1.112, mean diff. = − 0.08; 95% Cl of diff. = − 0.3166 to 0.1566) 
(Fig. 1b and Supplementary Fig. 1). It has been previously reported that excitotoxic damage derived from 
KA administration primarily affects pyramidal cells from CA1 and CA3 regions of the hippocampus. To 
corroborate that the increased cell death is associated with PrPC deletion, we focused on B6129 Prnp0/0 
and 129/Ola Prnp0/0 mice. We obtained coronal brain sections (dorsal hippocampus) from these mice 24 
hours after KA treatment and performed Fluoro-Jade B staining to determine the associated neurode-
generation in the hippocampus. Wild type mice were processed in parallel (Fig. 1c). B6129- Prnp0/0 mice 
displayed much more pronounced pyramidal cell damage, with higher numbers in CA1 than in CA3, 
than wild-type controls, in which no Fluoro-Jade B positive cells were observed. PrPC-dependent differ-
ences were also detected between 129/Ola- Prnp0/0 and 129/Ola-Prnp+/+ although cell death appeared to 
be restricted mostly to the CA3 region (Fig. 1c).
Taken together, these results support the notion that the genetic background of the different Prnp0/0 
mice plays a role in KA susceptibility22,23, with the FVB/N background more prone to seizures than 129/
Ola or the mixed genetic background B612926,49. The susceptibility of the FVB background49,50 probably 
masks participation of PrPC at this specific KA-dosage.
More relevantly, the present results demonstrate a role of PrPC in neuroprotection, since the phe-
notypic differences observed between Prnp0/0 and Prnp+/+ mice in B6129 PrnpZrchl/Zrchl (Supplementary 
Movie 1) are also reproduced in co-isogenic 129/Ola PrnpEdbg/Edbg mice (Supplementary Movie 2).
Decreased seizures in B6.129 PrnpZrchl/Zrchl compared to B6129 PrnpZrchl/Zrchl mice. In a sec-
ond set of experiments we used B6.129 PrnpZrchl/Zrchl mice generated after crossing the original B6129 
PrnpZrchl/Zrchl mice with C57BL/6 mice over several generations. In these experiments, B6129 PrnpZrchl/Zrchl 
mice were purchased directly from EMMA (Monterotondo, Italy) and they carried approximately ≈ 64% 
of C57BL/6 microsatellite markers (Charles River Laboratories) with ≈ 46% of non-C57BL/6 markers 
(129 in origin). We backcrossed these Prnp0/0 mice with C57BL/6 mice over several generations (8–10) 
to reduce the non-C57BL/6 microsatellite markers to ≈ 6.5–7%. The presence of C57BL/6 or 129 mark-
ers in all phenotypes used in the present study was determined by the genetic testing service at Charles 
River Laboratories. In the test, 110 microsatellite markers at approximately 15 cM intervals were ana-
lyzed, spreading across the 19 autosomes and the X chromosome, which distinguishes among 129 micro-
satellite markers ranging from 92 to 94% of C57BL/6 (in B6.129 PrnpZrchl/Zrchl mice). Thus B6129 and 
B6.129 PrnpZrchl/Zrchl mice were treated with 8 mg/kg b.w. (B6129 n = 8 and B6.129 PrnpZrchl/Zrchl n = 6) 
or 10 mg/kg b.w (B6129 n = 8 and B6.129 PrnpZrchl/Zrchl n = 9) of KA and the number of seizures was 
determined during the first 30 minutes, from 30 to 60 minutes and from 60 to 180 minutes postinjection. 
In this experiment each mouse received a KA injection every 30 minutes as above. Data revealed a rele-
vant number of seizures in B6129 PrnpZrchl/Zrchl Prnp0/0 mice compared with B6.129 PrnpZrchl/Zrchl Prnp0/0 
(KA 8 mg/kg P = 0.0021; KA 10 mg/kg P = 0.0086; Mann-Whitney U test confidence interval (CI) = 95% 
(Fig. 1d and Supplementary Movie 1). In addition, the differences between the numbers of seizures can 
be observed in both KA concentrations (8 and 10 mg/kg b.w). These data indicate that although PrPC 
plays a role in the increased susceptibility to KA as demonstrated above, the 129 associated genes also 
play a role in the observed results.
Increased susceptibility in B6.129-Prnp0/0 and 129/Ola- Prnp0/0 correlates with enhanced cell 
death, inflammatory markers and astrogliosis. Parallel histological sections to those processed 
in Fig. 1 KA-induced astrocytic activation and inflammatory response in B6129-Prnp0/0 (n = 5), 129/Ola- 
Prnp0/0 (n = 5) mice at their respective controls (n = 5 each genotype) (Fig. 2a). Immunohistochemical 
analysis of GFAP-positive cells in the hippocampus of PrPC-null mice (either B6129 or 129/Ola) 
revealed large numbers of positive cells in the hippocampal CA1-3 when compared to Prnp+/+ controls 
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(B6129-Prnp0/0 75.7 ± 1.24 vs B6129-Prnp+/+ 43.4 ± 1.06; P = 0.005 Mann-Whitney U test. 129/Ola- 
Prnp0/0 53.7 ± 1.44 vs 129/Ola-Prnp+/+ 42.9 ± 0.92; P = 0.0047 Mann-Whitney U test. Immunoreactive 
cells showed hypertrophic cell bodies and thicker glial processes (Fig. 2a). Moreover, quantitative real-time 
PCR data obtained from hippocampal samples 6 hours after KA-administration showed upregulation 
of the main pro-inflammatory markers TNFα (4.7-fold increase in B6129-Prnp0/0 (n = 3) P = 0.0046, 
Mann-Whitney U test and 3.8-fold increase in 129/Ola-Prnp0/0 (n = 3) (P = 0.0008, Mann-Whitney U 
test) vs respective wild type (B6129 n = 3 and 129/Ola n = 3) and IL1β (3.7-fold increase in B6.129- 
Prnp0/0 and 3.0-fold increase in 129/Ola- Prnp0/0 vs respective wild type (B6.129- Prnp0/0 P = 0.0046 and 
129/Ola Prnp0/0 P = 0.0004, and Mann-Whitney U test)) (Fig. 2b).
Chemical elimination of the GPI domain and of PrPC reduces neuroprotection to KA in 
Prnp-transfected N2a cells. The GPI anchor in PrPC, as in other GPI-proteins, is not only nec-
essary for the stability and attachment of the protein to the cell surface, but also for its association to 
specialized membrane microdomains (e.g., lipid rafts), its intracellular traffic and signal transduction 
events. In addition, the GPI group has been suggested as playing a role in prion disease toxicity, as 
transgenic mice expressing secreted forms of PrPC lacking its GPI-moiety showed no clinical symptoms 
despite accumulating PrPSc in plaques51. Because in our microsatellite analysis the C57BL/10-PrPGPIless 
mice (Tg44+/+ kindly provided by Dr. B. Chesebro) contained non-B10 regions in chromosome 3 and 
in chromosome 2 flanking the Prnp locus, we decided to check whether the degradation of the GPI 
binding domain of the PrPC leading to a decreased PrPC in the plasma membrane could overcome 
the neuroprotective function of PrPC (Fig.  3a–c). In addition, this approach would determine whether 
the neuroprotective effect against KA treatment of PrPC takes place at the membrane or intracellularly. 
Thus, N2a cells were treated either with Phospholipase C (PLC) enzyme or Glimepiride, a sulphony-
lurea approved for the treatment of diabetes mellitus, inducing the release of PrPC from the surface of 
prion-infected neuronal cells, which releases PrPC from the surface of neuronal cells52 (see methods for 
details). Decreased levels of PrPC after treatments were detected with western blot (pcDNA = 0.39 ± 0.021; 
pcDNA-PrPC = 0.91 ± 0.025; pcDNA-PrPC + PLC = 0.45 ± 0.013; pcDNA-PrPC + Gli = 0.496 ± 0.014) 
(Fig. 3a and Supplementary Fig. 2) or with immunocytochemistry in non-permeabilized cells (Fig. 3b) 
(pcDNA CTCF = 1.63 ± 0.09; pcDNA-PrPC CTCF = 6.44 ± 0.12. pcDNA-PrPC + Gli CTCF = 2.82 ± 0.20; 
pcDNA-PrPC + PLC CTCF = 2.063 ± 0.15. pcDNA vs pcDNA-PrPC t = 7.40, mean diff. = − 4.8, 95% 
CI of diff. = − 6.88 to − 2.72. pcDNA-PrPC vs pcDNA-PrPC + Gli t = 5.31, mean diff. = 3.6, 95% 
CI of diff. = 1.43 to 5.78. pcDNA-PrPC vs pcDNA-PrPC + PLC t = 6.02, mean diff. = 4.37, 95% CI of 
Figure 2. Increased astrogliosis, TNFα and IL1β expression in the hippocampus of B6129 PrnpZrchl/Zrchl 
Prnp0/0 and 129/Ola PrnpEdbg/Edbg Prnp0/0. (a) Examples of GFAP-positive immunoreactive cells in the 
stratum radiatum of the hippocampal CA1-3, 24 hours after KA administration in hippocampal coronal 
sections of B6129 PrnpZrchl/Zrchl Prnp+/+, B6129 PrnpZrchl/Zrchl Prnp0/0, 129/Ola PrnpEdbg/Edbg Prnp+/+, 129/Ola 
PrnpEdbg/Edbg Prnp0/0. Both Prnp-null mice show greater numbers of reactive astroglia than their wild-type 
controls. (b) RT-qPCR of TNFα and IL1β mRNA levels from hippocampal RNA extracts obtained from 
B6129 PrnpZrchl/Zrchl Prnp+/+, B6129 PrnpZrchl/Zrchl Prnp0/0, 129/Ola PrnpEdbg/Edbg Prnp+/+, 129/Ola PrnpEdbg/Edbg 
Prnp0/0 mice 6 hours after the last KA treatment (at 60 minutes). Plotted data (mean ± S.E.M.) were obtained 
from three independent experiments and represented as mean fold change induction. Abbreviations are as in 
Fig. 1. Scale bars represent 100 μ m. Asterisks indicate statistical significance (***P < 0.01 Mann-Whitney U 
test).
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diff. = 2.04 to 6.70. WST-derived results indicate that both treatments increased the sensitivity to KA 
(pcDNA vs pcDNA-PrPC t = 4.38, mean diff. = − 0.27, 95% CI of diff. = − 0.44 to − 0.10. pcDNA-PrPC 
vs pcDNA-PrPC + PLC t = 2.789, mean diff. = − 0.175, 95% CI of diff. = − 0.34 to − 0.005. pcDNA-PrPC 
vs pcDNA-PrPC + Gli t = 4.46, mean diff. = 0.28, 95% CI of diff. = 0.11 to 0.45 (Fig. 3c).
Enhanced cell death in the CA3 hippocampal region ΔF35 and ΔC4 mice compared to 
B6129 mice. Prnp0/0 Δ F35 (Δ F35) and Prnp0/0 Δ C4 (Δ C4) mice (Fig.  4a) were generated some 
years ago by nuclear injections of constructs into fertilized oocytes from B6129 PrnpZrchl/Zrchl mice53. 
The number of copies of the construct was estimated as 25 for Δ C4 and 70 for Δ F35 mice. However, 
brain extracts obtained from these mice revealed similar levels of PrP− Δ C4 ( Prnp+/+ = 0.755 ± 0.075; 
PrP− Δ C4 = 0.81 ± 0.03; P = 0.4; CI = 95%, Mann-Whitney U test) to wild-type but lesser amounts of 
PrP− Δ F35 than wild-type ( Prnp+/+ = 0.91 ± 0.01; PrP− Δ F35 = 0,70 ± 0.021; P = 0.0048, CI = 95%, 
Mann-Whitney U test) (Fig. 4b and Supplementary Fig. 3). Nevertheless only Δ F35 mice showed cer-
ebellar degeneration at around 60 days of life53 (Supplementary Fig. 4). Irrespective of the cell type, 
the expression of the truncated form may induce per se cell death in vivo54 as well as in vitro55. Thus 
in the next experiments we treated these mice with 8 mg/kg b.w. of KA following the above-mentioned 
protocol. Behavioural results reported a similar evolution between Δ C4 ( n = 11) and Δ F35 ( n = 15) 
Figure 3. Chemical release of PrPC from the cell surface impairs the neuroprotective function in KA-
treated N2a cells. (a) Example of western blot determination of PrPC levels in protein extracts of pcDNA, 
pcDNA-PrPC, pcDNA-PrPC + PLC and pcDNA-PrPC + Gli treated N2a cells. (b) Microphotographs 
illustrating PrPC levels in cells transfected with pcDNA or pcDNA-PrPC, and treated with PLC (pcDNA-
PrPC + PLC) or Gli (pcDNA-PrPC + Gli). PrPC (green) was detected in non-permeabilized cells with 6H4 
antibody. Note the decrease in PrPC after PLC and Gli treatments in (a) and (b). (c) Histogram showing 
the decrease in surviving cells after KA-treatment (5 mM overnight) determined with the WST-1 viability 
test after PLC or Gli treatment of pcDNA-PrPC transfected cells. Data (mean ± S.E.M.) were obtained from 
three independent experiments and represented as mean fold change. Scale bars represent 100 μ m. Asterisks 
indicate statistical significance (**P < 0.05, Bonferroni post hoc test).
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Figure 4. KA-induced seizures and neurotoxicity in ∆C4 and ∆F35 mice. (a) Scheme of PrPC and 
N-terminal truncated forms overexpressed in B6129 PrnpZrchl/Zrchl Prnp0/0 ∆C4 and B6129 PrnpZrchl/Zrchl 
Prnp0/0 ∆F35 transgenic mice. (b) Example of western blot detection of PrPC (6H4) expression in brain 
extracts obtained from untreated B6129 PrnpZrchl/Zrchl Prnp+/+and B6129 PrnpZrchl/Zrchl Prnp0/0, B6129 
PrnpZrchl/Zrchl Prnp0/0 ∆C4 and B6129 PrnpZrchl/Zrchl Prnp0/0 ∆F35 mice. Tubulin was used as a loading control. 
(c) KA-induced seizure sensitivity in adult B6129 PrnpZrchl/Zrchl Prnp0/0 ∆C4 mice in comparison to B6129 
PrnpZrchl/Zrchl Prnp+/+ and B6129 PrnpZrchl/Zrchl Prnp0/0 (upper panel). KA-induced seizure sensitivity in 5–7 
week-old B6129 PrnpZrchl/Zrchl Prnp0/0 ∆F35 mice in comparison to B6129 PrnpZrchl/Zrchl Prnp+/+, and B6129 
PrnpZrchl/Zrchl Prnp0/0 (lower panel). Bars represent the percentage of mice reaching each stage. (d) Fluoro-
Jade B staining in hippocampal sections of B6129 PrnpZrchl/Zrchl Prnp+/+, B6129 PrnpZrchl/Zrchl Prnp0/0, B6129 
PrnpZrchl/Zrchl Prnp0/0 ∆C4 and B6129 PrnpZrchl/Zrchl Prnp0/0 ∆F35 mice 24 hours after KA treatment (8 mg/
kg b.w.). The quantification of the Fluoro-Jade B-positive cells in the CA3 region is shown in the right plot. 
Scale bars represent 200 μ m. Abbreviations: DG, Dentate gyrus; CA1-3, hippocampal regions 1 and 3; h, 
hilus; gl, granule cell layer; ml, molecular layer; sr, stratum radiatum; slm, stratum lacunosum-moleculare; 
sl, stratum lucidum; sp, stratum pyramidale; so, stratum oriens. Asterisks indicate statistical significance 
(***P < 0.01, Bonferroni post hoc test).
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mice compared to B6129 Prnp Zrchl/Zrchl Prnp0/0 (n = 35 ) and B6129 Prnp+/+ ( n = 30) (Fig.  4c and 
Supplementary Movie 4). However, the number of dead was greater in Δ C4 (≈ 38%) and Δ F35 (≈ 15%) 
compared to B6129 Prnp Zrchl/Zrchl Prnp0/0 mice. These results also correlate with an increased presence of 
Fluoro-Jade B cells observed in histological sections of the hippocampus, especially in the CA3 region 
(Δ F35 = 87.12 ± 0.41; Δ C4 = 104.62 ± 0.088; B6129 Prnp Zrchl/Zrchl = 13,37 ± 0.055. B6129 Prnp Zrchl/Zrchl 
vs Δ F35 t = 7.577; mean diff. = − 73.75, 99% Cl of diff. = − 115.4 to − 32.1. B6129 Prnp Zrchl/Zrchl vs Δ C4 
t = 9.375; mean diff. = − 91.25, 99% CI of diff. = − 132.9 to − 49.6, Bonferroni post hoc test). (Fig.  4d). 
Taken together, these results indicate that the expression of the truncated form including the octare-
peat region (OR) with or without the Central Domain (CD) of PrPC potentiates the effects of the KA 
(<10 mg/kg b.w.), and they highlight the octarepeat domain as a key candidate in the neuroprotective 
functions of PrPC.
Acute transfection of pcDNA-PrP∆CD but not pcDNA-PrP∆F35 protects N2a cells from KA exci-
totoxicity in vitro. In order to corroborate in vitro the participation of the OR in PrPC-mediated neu-
roprotection to KA, we performed a viability assay using N2a cells. Cells were transfected with vectors 
encoding either the full length of Prnp or two truncated forms lacking CD (PrP∆CD, residues 95–133), 
which bridge the flexible amino proximal tail and the globular carboxy proximal domain, or else a longer 
deletion including the central domain (CD) plus the OR (PrP∆F35, residues 32–134) (Fig. 5a). After trans-
fection, levels of PrPC and its truncated forms in transfected cells were checked with western blotting 
(Fig. 5b and Supplementary Fig. 5). In addition, the expression of the truncated forms was strictly mod-
ulated to avoid inducing cell death during the experiments. Transfected cells were treated overnight with 
5 mM KA and further processed to WST-1 assays. Colorimetric WST-1 assay showed that PrPC and PrP∆CD 
transfection increased cell culture viability after KA treatment, an effect that was not observed in PrP∆F35 
transfected cells ( pcDNA = 0.54 ± 0.005; pcDNA-PrPC = 0.94 ± 0.06; pcDNA-PrP∆CD = 1.047 ± 0.012 
and pcDNA-PrP∆F35 = 0.88 ± 0.03. pcDNA vs pcDNA-PrPC t = 36.18; mean diff. = − 0.4, 99% CI of 
diff. = − 0.45 to 0.34. pcDNA vs pcDNA-PrP∆CD t = 45.83; mean diff. = − 0.506, 99% CI of diff. = − 0.55 
to 0.45. pcDNA-PrP∆CD vs pcDNA-PrP∆F35 t = 15.08, mean diff. = 0.166, 95% CI of diff. = 0.1282 to 0.20). 
Figure 5. KA-excitotoxicity in N2a cells transiently transfected with PrPC or PrP-∆CD and PrP-∆F35 
constructs. (a) Scheme illustrating domain organization in PrPC and its related PrP∆CD and PrP∆F35 mutants. 
(b) Example of western blot determination of the different PrPC constructs employed in the experiment. 
(c) WST-1 viability assay performed over N2a cells previously transfected with pcDNA3.1 (empty vector, 
pcDNA), pcDNA-PrPC, pcDNA-PrP∆CD and pcDNA-PrP∆F35 and treated overnight with 5 mM KA. Data 
were normalized with untreated controls. A clear reduction in cell viability was observed in pcDNA-
PrP∆F35 transfected cells when compared to those overexpressing pcDNA-PrPC. In contrast, pcDNA-
PrP∆CD transfected cells showed similar viability to pcDNA-PrPC transfected cells. Histograms represent 
the mean ± S.E.M. of three different experiments. Asterisks indicate statistical significance (**P < 0.05, 
***P < 0.01, Bonferroni post hoc test).
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pcDNA-PrPC vs pcDNA-PrP∆F35 t = 5.42, mean diff. = 0.06, 95% CI of diff. = 0.021 to 0.09) (Fig.  5c). 
These results reinforce the idea of the OR domain participating in the described neuroprotective role of 
PrPC to excitotoxic damage in N2a cells.
Discussion
Role of PrPC in neuroprotection against KA. The diversity of phenotypic changes described in 
Prnp-knockout mice has hindered the study of the physiological function of PrPC10. In fact the reported 
differences between Prnp+/+ and Prnp0/0 mice have led to certain controversial results, especially in 
terms of electrophysiology and susceptibility to excytotoxic insults. Several pieces of evidence, includ-
ing some from previous studies by our group using B6.129 Prnp Zrchl/Zrchl 2,18,21,40, support the idea that 
Prnp-knockout mice are more susceptible to KA, NMDA and PTZ, exhibiting an enhanced epileptic 
response and neurotoxicity in the hippocampus when compared to wild type controls17,19. Contradictory 
results have been published by other groups, who described an elevated threshold for epileptiform activ-
ity in Prnp0/0 hippocampal slices exposed to bicuculline, PTZ or zero-magnesium conditions24. Similar 
discrepancies have been found when analysing neurotransmission-associated parameters in mice devoid 
of PrPC34,35,37,38. Due to this lack of reproducibility between groups, the possibility that reported pheno-
types could be attributed to external factors, such as different mice strains (e.g.,25 or 32) or experimen-
tal procedures (age of mice, KA concentration, treatments, etc.) must be strongly considered. Indeed, 
age-dependent loss of LTP in PrPC-null mice56,57 has also been identified.
More recently, a comparative analysis between Prnp-knockout mouse strains has led to the proposal 
that the increased sensitivity to KA-induces seizures in Prnp-knockout mice is not associated with the 
absence of the protein but rather with inappropriate comparison with wild-type controls that differ in 
genetic background22,23,58. In this study, background influence in susceptibility to excitotoxic damage was 
corroborated by evaluating the onset of epileptic seizure of wild-type mice from B6129, B6.129,129/Ola 
and FVB/N strains. Our results show that FVB/N wild-type mice showed more seizures than B6129 and 
129/Ola mice, corroborating previous studies25,26,59. In addition, 129/Ola wild-type showed increased 
expression of PrPC that may also reduce the number of grade VI seizures.
In our study we observed the relevant effects of intraperitoneal injection of KA in B6129 PrnpZrchl/Zrchl 
Prnp0/0 (with ≈ 46% 129 microsatellites), B6.129 PrnpZrchl/Zrchl Prnp0/0 (with ≈ 6–7% 129 microsatellites) 
and 129/Ola-Prnp0/0 mice (with 100% 129 background) compared with the appropriate wild-type controls. 
Results indicate a decline in the epileptic seizures when low numbers of 129 microsatellites are present in 
B6.129 PrnpZrchl/Zrchl Prnp0/0. These results point to polymorphisms of some of the “Prnp- flanking genes” 
as masking the participation of PrPC in neuroprotection, as reported in other processes30. Analysis of 
the 9 genes functions using gene ontology and Pubmed searches indicates that Prex160, SIRPα 61, Traf162, 
Thbs163,64, Rmdn365, Tyro366,67, Slc30a468, Mertk69 and B2m70 are involved in neurotransmission, LTP 
and neuroprotection. Whether polymorphisms in these genes participate in these effects warrants fur-
ther study. However, the phenotypic differences observed between 129/Ola Prnp+/+ and 129/Ola Prnp0/0 
mice could only be associated with Prnp-deletion, as no possible genetic variability exists between the 
two. These results differ from those recently published by Striebel and coworkers23 who didn’t observe 
PrPC-linked neuroprotection despite using the same mouse strain. These contradictory results may be 
due to KA-dosage or to minor differences in the experimental procedure. Furthermore, we must not 
forget that this neuroprotective property of PrPC is further supported by other in vivo models, such as 
transient knockdown of Prnp homologs in zebrafish71, and also some in vitro experimental approaches 
including PrPC downregulation and detachment of the plasma membrane in neuronal primary cultures 
and neuroblastoma cell lines (18–20 and present results).
In conclusion, our findings support the notion that PrPC is involved in neuroprotection to KA-induced 
seizures and excitotoxicity and that it actively participates in the increased epileptic response observed in 
mice devoid of PrPC. In parallel, as yet unknown factors associated with Prnp-flanking genes also affect 
KA susceptibility.
The neuroprotective function of PrPC depends on membrane anchoring. Our results indicate 
that the neuroprotective function of PrPC against KA in N2a cells depends on membrane anchoring. The 
interaction of different regions of PrPC with plasma membrane through the GPI domain has been con-
sidered necessary to induce the clinical symptoms in GPI-negative transgenic mice (C57BL/10-PrPGPIless 
mice)51,72. In fact, the injection of antibodies directed to the α 1 and α 3 regions of the PrPC induces neu-
rotoxic effects73. These results have also been corroborated in newly developed mice lacking the globular 
domain (FTgpi mice)74. In fact, these results corroborate previous observations75. Taken together, these 
studies suggest that the proximity of the flexible tail (N-terminal domain) to the plasma membrane 
triggers intracellular oxidative stress responses leading to cell death74,76. Under this scenario we can 
consider that our data reinforce the idea that the integrity of the N-terminal domain is mandatory for 
neuroprotection (see below) as well as the notion that membrane interaction is a necessary part of the 
neuroprotective function reported in vivo.
The neuroprotective function of PrPC is abolished in the absence of the OR of PrPC. Structural 
analysis of PrPC architecture has determined different functionally relevant domains in this protein 
(see77,78 for review). Besides the highly conserved hydrophobic domain, the flexible and unstructured 
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N-terminus region includes a copper binding site consisting of four tandem repeats of the sequence 
PHGGGWGQ, which seems to be involved in the endocytic process of the protein79 and copper homeo-
stasis3. In fact a recent study indicates a relevant role of copper binding in the neuroprotective function 
of PrPC modulating NMDA receptor48. In our study we developed in vivo as well as in vitro tests to 
check the involvement of the OR domain as a mediator of PrPC neuroprotective function in a model of 
KA treatment. The behavioural and histological data presented here by Δ C4 and Δ F35 mice revealed 
increased cell death in the hippocampus of the KA injected mice compared to B6129 Prnp0/0 (genetic 
background of these mice). In parallel, the CD is not involved in the neuroprotective functions of PrPC 
(at least in N2a cells) since their absence does not modify these properties when compared to full length 
PrPC, in contrast to the absence of the OR regions.
The overexpression of PrP− Δ F35 in a B6129 PrnpZrchl/Zrchl Prnp0/0 background leads to cerebellar 
neurodegeneration53, but not hippocampal degeneration55 (Supplementary Fig. 4). In contrast, Δ C4 
mice (with similar background) do not show cerebellar or hippocampal degeneration, but when sub-
jected to controlled ischemia show significantly greater oxidative stress damage when compared to wild 
type mice80. This also happens when PrP− Δ F35 is overexpressed in HEK293 cells, leading to increased 
Caspase 3 activity in transfected cells and cell death55. Truncated forms of PrPC lacking the OR inter-
fere with PrPC endocytosis via clathrin-coated vesicles and beta-cleavage of PrPC, respectively, thereby 
impairing the antioxidative functions of PrPC81,82. Thus it is reasonable to consider that cells with an 
intrinsic deficit in oxidative stress homeostasis may also be more prone to KA treatment if the appropri-
ate KA receptors are also expressed, as happens in the hippocampus83–85.
As indicated above, using antibody-mediated degeneration, Sonati et al., demonstrated that ligands 
directed to the α 1 and α 3 helices of the PrPC globular domain induce cerebellar cell death by activat-
ing oxidative stress that can be overcome by deletions in the OR region73. This also happens in FTgpi 
mice lacking the α 1–α 3 helix region of the PrPC 74. In addition, mice lacking the Δ CD also reported 
white matter pathology and peripheral neuropathy86. Surprisingly, the reported degeneration of the Δ CD 
mice could be reversed by coexpression of PrPC lacking all octarepeats86. These data are in contrast to 
a recent study indicating that the antibody ICSM18 (recognizing aa143–153 of PrPC) does not induce 
cell death87. In our experiments, we observed that cells transfected with PrP− Δ CD are able to over-
come KA-mediated cell death as are those transfected with full length PrPC, in contrast to PrP− Δ F35 
transfected N2a cells. Our in vitro experiments are different from the in vivo situation, since an effect of 
ligands in the CD regions is unlikely; rather, they suggest a parallel effect of KA excytotoxicity plus the 
homeostatic imbalance induced by the absence of the 32–93 region of the overexpressed PrPC. Despite 
the existing data, the precise mechanism underlying OR-dependent neuroprotection remains to be elu-
cidated in the above-mentioned studies73,87,88.
In conclusion, our study dissects the effects of the intraperitoneal injection of various doses of KA 
in several Prnp mouse models and indicates that: i) PrPC plays a role in neuroprotection in KA-treated 
cells and mice; ii) for this role PrPC should be linked to the membrane; iii) polymorphisms of some 
unidentified “Prnp-flanking genes” play a parallel role to PrPC in the KA-mediated responses in B6129 
and B6.129 PrnpZrchl/Zrchl Prnp0/0 mice; and iv) the absence of the aa32–93 region negatively affects the 
neuroprotective function of PrPC in KA-treated cells.
Methods
Reagents and antibodies. KA, glimepiride and phospholipase C were purchased from Sigma (Poole 
Dorset, UK). Fluoro-Jade B was from Millipore (Billerica, MA), SYBR green (Applied Biosystems, USA) 
and WST− 1 reagents were from Roche (Basel, Switzerland). Lipofectamine plus was from Invitrogen 
(Carlsbad, CA). The following antibodies were used in this study: Anti-PrP SAF61 mouse monoclonal 
antibody (1:1000 diluted) antibody was from Spi-Bio (Cayman Chemical, Massy, France) and anti-PrP 
6H4 mouse monoclonal antibody (1:5000 diluted western blotting and 1:250 immunocytochemistry) 
antibody was from Prionics (Schlieren, Switzerland). Mouse monoclonal antibody anti-tubulin (1:10000 
diluted) was from Sigma (Poole Dorset, UK) and rabbit-raised polyclonal antibody against GFAP (1:500 
diluted) was from Millipore (Billerica, MA).
Animals. Adult male C57Bl6/129sv-Prnp0/0 (B6129 PrnpZrchl/Zrchl Zurich I) mice were purchased from 
the European Mouse Mutant Archive (EMMA, Monterotondo, Italy). The FVB/N animals were either 
wild-type or homozygous for the deletion of Prnp gene. 129/Ola PrnpEdbg/Edbg Prnp+/+ and 129/Ola Prnp0/0 9 
were obtained from Dr. J. Manson (Edinburgh). B6129 PrnpZrchl/Zrchl mice were backcrossed for 8 genera-
tions to obtain 6–7% of 129 microsatellites (B6.129 PrnpZrchl/Zrchl). Transgenic B6129 Prnp0/0 PrP∆C4 89 and 
B6129 Prnp0/0 PrP∆F35 53 were obtained from Prof. A. Aguzzi. To avoid putative background-specific differ-
ences between mice, all of the experiments were conducted using littermates derived from heterozygous 
(Prnp+/0 Δ F35+) and Prnp0/0 parents. Specific primers for Prnp genotyping were designed in our laboratory 
based on the original P10 and P3 primers described elsewhere8. PrP∆F35 transgene was detected by using 
5′ -CCTGGGACTCCTTCTGGTACCGGGTGACGC-3′ and 5′ -CAACCGAGCTGAAGCATTCTGCCT
-3′ set of primers and PrP∆C4 with 5′ -GGCTGGGCTTGTTCCACTGATTATGGG-3′ and 
5′ -CAACCGAGCTGAAGCATTCTGCCT-3′ . Tg44+/+ mice expressing anchorless PrPC 51 on a C57Bl/10 
background were obtained from Dr. Bruce Chesebro (Laboratory of Persistent Viral Diseases, Rocky 
Mountain Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, MT 59840, 
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USA). A total of 83 litters (193 animals) were used in the present study. All experiments were performed 
under the guidelines and protocols of the Ethical Committee for Animal Experimentation (CEEA) of the 
University of Barcelona, and the protocol for the use of animals in this study was reviewed and approved 
by the CEEA of the University of Barcelona (CEEA approval #115/11 and 141/15).
KA administration in mice and seizure analysis. Convulsive non-lethal seizures in mice were 
induced by administration of KA in a multiple dose protocol. Fresh KA solution was prepared for each 
experiment. Animals were weighed and intraperitoneally injected with 8 or 10 mg/kg KA (b.w.) dissolved 
in 0.1 M PBS, pH 7.2. at 0 min, 30 min and 60 min. In parallel mice, 0.1 M PBS, pH 7.2 was injected 
as control (vehicle). Adult (2–3 months old) animals were used in all experiments except for B6129 
PrnpZrchl/Zrchl Prnp0/0 PrP∆C4 PrP∆F35 and their respective controls, which were used at 5–7 weeks-old due 
to their described early lethality53.
After KA-injection mice were distributed in boxes (1–5 mouse/box) and the behaviour of the mice 
was recorded for 4 hours using a digital video camera (SONY DCR-HC30E Digital video camera). 
Seizure intensity was evaluated during the 4 hours after the first injection using the following criteria: 
grades I-II: hypoactivity and immobility, grades III-IV: hyperactivity and scratching, grade V: loss of 
balance control and intermittent whole-body convulsions and grade VI: continuous seizures and bounc-
ing activity (commonly referred to as ‘popcorn’ behaviour). The characterization of seizure intensity was 
developed in two stages. First seizures were analysed in situ after KA-injections in the Molecular and 
Cellular Neurobiotechnology Laboratory (IBEC) by P.C., F.Ll. and A.M-A. (B6129 PrnpZrchl/Zrchl Zurich 
I, B6.129 PrnpZrchl/Zrchl, B6129 Prnp0/0 PrP∆C4, B6129 Prnp0/0 PrP∆F35, FVB/N Prnp0/0 mice strains and its 
respective controls) and in the Centro de Investigación en Sanidad Animal (CISA-INIA) by P.C, P.A-C., 
J.C.E. (129/Ola Prnp0/0 and 129/Ola PrnpEdbg/Edbg Prnp+/+). After this initial characterization that included 
time of the appearance of seizures, scale of seizures, etc, video recordings of each experiment were ana-
lysed by J.A.D.R. at IBEC and J.M.T. at CISA-INIA without knowledge of the results of the previous 
in situ analysis. Afterwards, a contingency table was generated by comparing both analyses and the final 
data were plotted. Grades I to IV were grouped together for better data representation, as all animals 
tested reached these four epileptic stages. The statistical analysis of the obtained data was performed 
using Mann–Whitney U non-parametric test using Prism 5.0c (Mac OsX, Grahpad). Data are presented 
as percentage or as mean ± standard error of the mean (S.E.M.). A value of ***P < 0.01 was considered 
statistically significant.
Western blotting. Brain samples from non-treated mice were homogenized (10% wt/vol) in ice-cold 
lysis buffer—50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% (wt/vol) Triton X-100, 0.5% (wt/vol) Nonidet 
P-40 (IGEPAL; Sigma), glycerol 10%, 1 mM EDTA, 1 mM EGTA, and protease and phosphatase inhibi-
tors—using a motor-driven, glass-Teflon homogenizer in ice, and then centrifuged at 15,000g for 20 min. 
Protein concentration was quantified with BCA kit (Pierce). Protein extracts were boiled in Laemmli 
sample buffer at 100 °C for 5 min. Equal amounts of total protein were separated with 6–10% SDS-PAGE 
electrophoresis, electrotransferred to polyvinylidene fluoride (PVDF) membranes (Millipore), and probed 
with indicated antibodies. Visualization of bound antibodies was performed using goat anti-mouse HRP 
(1:4000 diluted; Dako, Glostrup, Denmark) and the ECL Plus kit (Amersham-Pharmacia Biotech, GE 
Healthcare Bio-Sciences, Piscataway, NJ, USA).
Densitometry and statistical processing of processed films. For quantification, developed films 
were scanned at 2400 × 2400 dpi (i800 MICROTEK high quality film scanner), and the densitometric 
analysis of the different PrPC bands was performed in each case using Quantity One Image Software 
Analysis (Biorad). Each densitometric value of PrPC and truncated form Δ C4, Δ F35 and Δ CD (0–255 
gray scales) was normalized with the corresponding Tubulin densitometric values (0–255 gray scale). 
Three different experiments were used in each analysis unless specified. The statistical analysis of the 
obtained data was performed using Bonferroni post hoc test (Multiple comparison test) or Mann-Whitney 
U non-parametric test using Prism 5.0c (Mac OsX, Grahpad). Data are presented as mean ± standard 
error of the mean (S.E.M.). A value of **P < 0.05 was considered statistically significant.
Fluoro-Jade B staining. Mice were perfused with 4% paraformaldehyde dissolved in 0.1 phosphate 
buffer, pH 7.3 24 hours after the first KA injection, post-fixed overnight in the same fixative, and cryopro-
tected in 30% sucrose. 30 μ m-thick coronal brain sections were obtained in a freezing microtome (Leica, 
Wetzlar, Germany). Sections containing dorsal hippocampus (Bregma = − 1.2 to − 1.990) were rinsed for 
2 h in 0.1 M Tris, pH 7.4, mounted and air dried at room temperature overnight. The next day, sections 
were pre-treated for 3 min in absolute ethanol, followed by 1 min in 70% ethanol and 1 min in distilled 
water. They were then oxidized in a solution of 0.06% KMnO4 for 15 min. After three rinses of 1 min 
each in distilled water, the sections were incubated for 30 min in a solution of 0.001% Fluoro-Jade B 
(Chemicon) containing 0.01% of DAPI (Sigma) in 0.1% acetic acid. The slides were rinsed in deionized 
water for 3 min each, dried overnight, cleared in xylene, cover-slipped with Eukitt (Merck, Darmstadt, 
Germany) and examined using an Olympus (Hamburg, Germany) BX61 epifluorescence microscope. 
The statistical analysis of the obtained data was performed using Bonferroni post hoc test (Multiple 
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comparison test) using Prism 5.0c (Mac OsX, Grahpad). Data are presented as mean ± standard error of 
the mean (S.E.M.). A value of ***P < 0.01 was considered statistically significant.
Histology and immunofluorescence. For histology, mice were perfused with phosphate buffered 
4% paraformaldehyde, pH 7.3 24 hours after the first KA injection, post-fixed overnight in the same 
fixative, and cryoprotected in 30% sucrose as above. A freezing microtome (Leica, Wetzlar, Germany) 
was used to obtain 30 μ m-thick coronal sections, which were rinsed in 0.1 M PBS before 1 hour’s incu-
bation at room temperature in 0.1 M PBS containing 0.2% gelatin, 10% normal goat serum, 0.2% gly-
cine, and 0.2% Triton X-100. Sections were then incubated overnight at 4 °C with indicated primary 
antibodies. After washing in 0.1 M PBS containing 0.2% Triton X-100, sections were incubated with 
goat anti-rabbit Alexa Fluor 568-tagged secondary antibody (1:200 diluted; Molecular Probes, Eugene, 
OR, USA), washed in 0.1 M, PBS and mounted in Fluoromount (Vector Labs, Burlingame, CA, USA). 
Immunohistochemical controls, which included omission or substitution of primary anti-GFAP antibody 
by either normal rabbit serum prevented immunostaining. For quantification of GFAP-positive astro-
cytes in the stratum radiatum of the dorsal hippocampal region, immunoreacted sections (5 sections 
of each mouse, n = 5 mice per genotype) were photodocumented with an Olympus BX61 fluorescence 
microscope equipped with a cooled DP12L camera. Photomicrographs were obtained using a 40X objec-
tive with identical time exposure (100–150 ms) between preparations from each wild-type and respective 
knockout mouse. No modifications were applied to the obtained pictures. Numbers of GFAP-expressing 
cells were determined by counting positive cells in five frames (250 × 200 μ m) corresponding to the hip-
pocampal CA1-3 regions of five mice of each genotype. Data were expressed as mean ± standard error 
of the mean (S.E.M). The statistical analysis of the obtained data was performed using Mann–Whitney 
U non-parametric test using Prism 5.0c (Mac OsX, Grahpad). A value of P < 0.01 was considered sta-
tistically significant.
RT-qPCR. Total RNA from hippocampal samples obtained from treated (6 h after KA-administration) 
and non-treated mice was purified with the mirVana isolation kit (Ambion, Austin, TX, USA) 
and used to make the single-stranded cDNAs required as templates for the RT-qPCR amplification. 
Sets of primers used in this study were: for TNFα 5′ - AGCAAACCACCAAGTGGAGGA- 3′ and 
5′ -GCTGGCACCACTAGTTGGTTGT- 3′ ; and for ILβ 5′ - TTGTGGCTGTGGAGAAGCTGT- 3′ and 
5′ - AACGTCACACACCAGCAGGTT- 3′ . The reaction was performed with the Roche LightCycler 
480 detector, using 2x SYBR Green Master Mix (Roche) as reagent, as indicated by the manufacturer. 
Amplification protocol consisted of a denaturation-activation cycle (95 °C for 10 min) followed by 40 
cycles of denaturation-annealing-extension (95 °C, 15 sec; 60 °C, 40 sections; 72 °C, 5 sec; 98 °C, con-
tinuous). LightCycler 480 software was used for mRNA quantification. The data were analysed using 
the ΔΔCt method, which provides the target gene expression values as fold changes in the problem 
sample compared with a calibrator sample. Both problem and calibrator samples were normalized by 
the relative expression of a housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase [GAPDH]). 
These analyses developed 3 different samples. The statistical analysis of the obtained data was performed 
using Mann–Whitney U non-parametric test using Prism 5.0c (Mac OsX, Grahpad). Data are presented 
as mean ± standard error of the mean (S.E.M.). A value of ***P < 0.01 was considered statistically sig-
nificant.
Cell culture and treatments. The murine neuroblastoma cell line Neuro2a (N2a) expressing low 
levels of PrPC was grown at 37 °C, 5.5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 4.5 g/L glucose, 10% fetal bovine serum (FBS) and antibiotics (Invitrogen-Life Technologies, 
Barcelona, Spain). For vector transfection, cells were plated at 1 × 105 cells/well in a 24-well plate and 
transiently transfected the next day using Lipofectamine 2000 reagent in Optimem medium, as indicated 
by the manufacturer (Invitrogen-Life Technologies). Four hours after transfection, cells were washed 
and the medium was replaced with DMEM containing 10% FBS. PrPC expression after transfection was 
checked with western blot analysis. In a first set of experiments, N2a cell cultures were transiently trans-
fected with pcDNA and pcDNA-PrPC and maintained in vitro at 37 °C, 5.5% CO2. Cells were deprived 
for 24 h and treated with Glimepiride 20 μ M and 0.2 u/ml PLC (final concentration). We used both treat-
ments since some reports indicate that Glimepiride may act on ATP-dependent K+ channels that may 
also affect cell survival91. One hour later, 5 mM KA dissolved in 0.1 M PBS was added to the media. After 
treatment, cultures were rinsed twice in KA-free culture medium, and cell viability was determined with 
WST-1 viability assay (see below). In parallel, non-permeabilized cells were processed to PrPC detection 
by immunofluorescence using the 6H4 antibody and a goat anti-mouse Alexa Fluor 488–tagged sec-
ondary antibody (1:200 diluted; Molecular Probes). For fluorescence quantification of cell-bound Alexa 
Fluor 488, immunoreacted cultures (n = 10 per experimental group) were photodocumented with an 
Olympus BX61 + DP12L camera. Photomicrographs were obtained using a 20X objective with identical 
time exposure (250–300 ms) for preparations from each group. No modifications were applied to the 
obtained pictures. Fluorescence intensity was determined using ImageJ by measuring the corrected total 
cell fluorescence (CTCF) as: CTCF = integrated density – (area of selected N2a mesured cells x mean 
fluorescence of background). Data were expressed as mean ± standard error of the mean (S.E.M). The 
statistical analysis of the obtained data in these experiments was performed using Bonferroni post hoc 
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test (Multiple comparison test) using Prism 5.0c (Mac OsX, Grahpad). A value of P < 0.05 was consid-
ered statistically significant. These experiments were repeated four times. In a second set of experiments, 
N2a cells were transfected with pcDNA3.1, pcDNA3.1-PrPC, pcDNA3.1-PrP∆CD and pcDNA3.1-PrP∆F35. 
KA (5 mM) treatment was carried out on serum-deprived cells 24 h after transfection. Cell viability 
was determined using a commercially available WST-1-based assay. Cell cultures were incubated with 
WST-1 reagent for 2 hours. Then absorbance at 450 nm was measured in a multiwell plate reader (Merck 
ELISA System MIOS). Data were normalized with A450 in untreated controls. pcDNA3.1-PrPC, pcD-
NA3.1-PrP∆CD and pcDNA3.1-PrP∆F35 were kind gifts from Prof. D. Harris (Boston University) and Prof. 
A. Aguzzi (University Hospital of Zurich). These experiments were repeated five times. The statistical 
analysis of the obtained data in these experiments was performed using Bonferroni post hoc test (Multiple 
comparison test) using Prism 5.0c (Mac OsX, Grahpad). Data are presented as mean ± standard error of 
the mean (S.E.M.). Values of **P < 0.05 and ***P < 0.01 were considered statistically significant.
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